Skip to main content
RIGL logo

Rigel Pharmaceuticals, Inc.

RIGLNASDAQHealthcareBiotechnology

$47.25Today:- (-)1Y +68.09%

As of Oct 15, 2026 close

Market cap
$924.68M
P/E (TTM)
2.87
Forward P/E
1.42
Dividend yield
-
52-week range
$24.95$52.24
Volume (live)
-
Avg. volume (3M)
228.85K

Rigel Pharmaceuticals (RIGL) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Rigel Pharmaceuticals had a P/E ratio of 2.12 (down from 16.95), return on equity of 185.9%, debt-to-equity of 0.14 (down from 30.40) and a current ratio of 2.42 (up from 2.13). A current ratio of 2.42 means current assets exceed current liabilities.

Rigel Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio2.1216.95----
Forward P/E10.4917.39----
P/S Ratio2.641.652.162.243.275.45
P/B Ratio1.9990.11-8.83-19.0414.9217.38
Price/Tangible Book2.12---14.9217.38
Price/FCF10.289.43--86.30-
Price/OCF10.289.41--77.09-
Enterprise Value Ratios
EV/Revenue2.381.872.522.332.905.15
EV/EBITDA5.4812.69----
EV/EBIT5.5913.86----
EV/FCF9.2710.67--76.67-
Profitability & Returns
Return on Equity (ROE)185.94%---699.04%-55.63%-67.72%
Return on Assets (ROA)23.15%10.75%-10.18%-24.34%-8.77%-14.04%
Return on Invested Capital (ROIC)79.47%51.25%-30.81%-178.67%-312.65%-739.58%
Return on Capital Employed (ROCE)30.30%24.00%-32.00%-85.00%-18.80%-41.70%
Leverage & Solvency Ratios
Debt/Equity0.1430.40-3.64-6.453.001.15
Debt/EBITDA0.413.68----
Debt/FCF0.703.18--17.38-
Liquidity Ratios
Current Ratio2.422.131.861.782.432.18
Quick Ratio2.081.881.641.512.211.79
Efficiency Ratios
Asset Turnover0.871.270.930.771.000.84
Inventory Turnover3.205.502.765.1710.8212.21
Yield & Distribution Ratios
Earnings Yield47.21%5.90%-9.92%-22.59%-3.95%-5.03%
FCF Yield9.73%10.61%-2.27%-28.62%1.16%-9.04%
Buyback Yield-6.52%-1.64%-2.07%0.00%-1.03%-0.81%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Rigel Pharmaceuticals Financial Ratios

What is Rigel Pharmaceuticals's P/E ratio?

Rigel Pharmaceuticals's P/E ratio was 2.12 for fiscal 2025 (period ended Dec 31, 2025). It was 16.95 a year earlier.

What is Rigel Pharmaceuticals's return on equity?

Rigel Pharmaceuticals's return on equity (ROE) was 185.9% for fiscal 2025 (period ended Dec 31, 2025).

What is Rigel Pharmaceuticals's debt-to-equity ratio?

Rigel Pharmaceuticals's debt-to-equity ratio was 0.14 for fiscal 2025 (period ended Dec 31, 2025). It was 30.40 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition